{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Jacksonville&page=79&state=Florida",
    "query": {
      "state": "Florida",
      "city": "Jacksonville",
      "page": 79
    },
    "page_size": 10
  },
  "pagination": {
    "page": 79,
    "page_size": 10,
    "total_count": 7650,
    "total_pages": 765,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Jacksonville&page=80&state=Florida&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Jacksonville&page=78&state=Florida&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T00:16:56.872Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05534984",
      "title": "Study of Tecovirimat for Human Mpox Virus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "MPOX"
      ],
      "interventions": [
        {
          "name": "Tecovirimat Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Tecovirimat",
          "type": "DRUG"
        },
        {
          "name": "Tecovirimat Oral Capsule (Open Label)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 719,
      "start_date": "2022-09-08",
      "completion_date": "2025-02-22",
      "has_results": true,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-11-21T00:16:56.872Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05534984"
    },
    {
      "nct_id": "NCT01793233",
      "title": "Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Anaplastic Large Cell Lymphoma",
        "Burkitt Lymphoma",
        "Diffuse Large B-Cell Lymphoma",
        "Hodgkin Lymphoma",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "29 Years",
        "sex": "FEMALE",
        "summary": "Up to 29 Years · Female only"
      },
      "enrollment_count": 203,
      "start_date": "2013-06-17",
      "completion_date": "2024-06-30",
      "has_results": false,
      "last_update_posted_date": "2024-08-26",
      "last_synced_at": "2026-11-21T00:16:56.872Z",
      "location_count": 97,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01793233"
    },
    {
      "nct_id": "NCT04226547",
      "title": "Amplatzer Amulet LAAO vs. NOAC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Stroke",
        "Bleeding"
      ],
      "interventions": [
        {
          "name": "Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder)",
          "type": "DEVICE"
        },
        {
          "name": "Non-Vitamin K Oral Antagonists",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Abbott Medical Devices",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2650,
      "start_date": "2020-07-07",
      "completion_date": "2031-04",
      "has_results": false,
      "last_update_posted_date": "2026-02-10",
      "last_synced_at": "2026-11-21T00:16:56.872Z",
      "location_count": 79,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04226547"
    },
    {
      "nct_id": "NCT00670358",
      "title": "Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "polymorphism analysis",
          "type": "GENETIC"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 138,
      "start_date": "2008-08-25",
      "completion_date": "2024-10-04",
      "has_results": true,
      "last_update_posted_date": "2025-01-10",
      "last_synced_at": "2026-11-21T00:16:56.872Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00670358"
    },
    {
      "nct_id": "NCT00066248",
      "title": "Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Tumor",
        "Central Nervous System Tumors",
        "Cachexia",
        "Leukemia",
        "Lymphoma",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "cyproheptadine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "megestrol acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "2 Years to 20 Years"
      },
      "enrollment_count": 70,
      "start_date": "2003-06",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2014-02-03",
      "last_synced_at": "2026-11-21T00:16:56.872Z",
      "location_count": 40,
      "location_summary": "Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00066248"
    },
    {
      "nct_id": "NCT01032044",
      "title": "CLE for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Barrett Syndrome",
        "Barrett's Syndrome",
        "Barrett's Esophagus",
        "Barrett Esophagus",
        "Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Standard endoscopic evaluation",
          "type": "DEVICE"
        },
        {
          "name": "pCLE guided evaluation",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Mauna Kea Technologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 164,
      "start_date": "2010-02",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2016-04-22",
      "last_synced_at": "2026-11-21T00:16:56.872Z",
      "location_count": 4,
      "location_summary": "Jacksonville, Florida • Chicago, Illinois • Kansas City, Missouri + 1 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01032044"
    },
    {
      "nct_id": "NCT01404234",
      "title": "Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Pseudomonas Aeruginosa"
      ],
      "interventions": [
        {
          "name": "AZLI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "Up to 12 Years"
      },
      "enrollment_count": 61,
      "start_date": "2011-12",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2014-05-29",
      "last_synced_at": "2026-11-21T00:16:56.872Z",
      "location_count": 10,
      "location_summary": "Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01404234"
    },
    {
      "nct_id": "NCT00106509",
      "title": "A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Clostridium Enterocolitis",
        "Pseudomembranous Colitis"
      ],
      "interventions": [
        {
          "name": "tolevamer potassium-sodium (GT267-004)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 520,
      "start_date": "2005-03",
      "completion_date": "2007-02",
      "has_results": false,
      "last_update_posted_date": "2015-03-05",
      "last_synced_at": "2026-11-21T00:16:56.872Z",
      "location_count": 99,
      "location_summary": "Phoenix, Arizona • Rogers, Arkansas • Burbank, California + 81 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00106509"
    },
    {
      "nct_id": "NCT01147809",
      "title": "Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thrombocytopaenia"
      ],
      "interventions": [
        {
          "name": "Eltrombopag olamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2010-06",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-04-18",
      "last_synced_at": "2026-11-21T00:16:56.872Z",
      "location_count": 33,
      "location_summary": "Sedona, Arizona • Hot Springs, Arkansas • Rancho Cucamonga, California + 29 more",
      "locations": [
        {
          "city": "Sedona",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Rancho Cucamonga",
          "state": "California"
        },
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01147809"
    },
    {
      "nct_id": "NCT05803421",
      "title": "A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Obesity",
        "Overweight or Obesity",
        "Overweight",
        "Cardiovascular Diseases",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Orforglipron",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2749,
      "start_date": "2023-04-03",
      "completion_date": "2026-03-16",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-11-21T00:16:56.872Z",
      "location_count": 173,
      "location_summary": "Daphne, Alabama • Mobile, Alabama • Pelham, Alabama + 149 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Pelham",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05803421"
    }
  ]
}